Chien-Liang Glenn Lin

This inventor holds 6 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: The Brigham and Women's Hospital, Inc., The Ohio State University. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chien-Liang Glenn Lin. Retrieved from https://idiyas.com/inventor/chien-liang-glenn-lin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 6 (Patent Applications = 1)

% Patents Active = 66.7

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 2.2

ph-index = 1

Forward Citations = 9(Granted Patents)

Company Filing History:

6 out of 1,430

The Brigham and Women's Hospital, Inc.

patents

6 out of 1,584

The Ohio State University

patents

where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12747227 - EAAT2 activators and methods of using thereof (2026-09-29),

2. 12286420 - EAAT2 activators and methods of using thereof (2025-04-29),

3. 11702403 - EAAT2 activators and methods of using thereof (2023-07-18),

4. 11377436 - EAAT2 enhancing molecules (2022-07-05),

5. 10787433 - Pyridazine derivatives as EAAT2 activators (2020-09-29),

6. 9447075 - Pyridazine derivatives as EAAT2 activators (2016-09-20),

Title: Chien-Liang Glenn Lin: Innovator in EAAT2 Activators

Introduction

Chien-Liang Glenn Lin is a notable inventor based in Columbus, OH (US). He has made significant contributions to the field of biotechnology, particularly in the development of compounds that target excitatory amino acid transporter 2 (EAAT2). With a total of 6 patents to his name, Lin's work is paving the way for new therapeutic approaches.

Latest Patents

Among his latest patents, Lin has disclosed innovative compounds that activate EAAT2. These compounds are designed to treat or prevent diseases, disorders, and conditions associated with glutamate excitotoxicity. His research focuses on the potential of these activators to provide new avenues for treatment in various neurological conditions.

Career Highlights

Throughout his career, Lin has worked with prestigious institutions such as The Brigham and Women's Hospital and The Ohio State University. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Lin has collaborated with notable colleagues, including Kevin J Hodgetts and Gregory D Cuny. These partnerships have enhanced his research and expanded the impact of his inventions.

Conclusion

Chien-Liang Glenn Lin is a prominent figure in the field of biotechnology, with a focus on EAAT2 activators. His innovative work and collaborations continue to influence the development of new therapeutic strategies.

Profile summary based on public USPTO records.